2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK
  5. CDK11 Isoform

CDK11

CDK11 is a serine/threonine cyclin-dependent kinase that regulates transcription, RNA splicing, apoptosis, and cell-cycle progression, thereby supporting cellular proliferation and survival programs[1][2]. Mechanistically, CDK11 participates in transcriptional complexes and RNA-processing pathways, while mitosis-associated CDK11 activity contributes to cytokinetic abscission through regulation of Aurora B-dependent checkpoint signaling[1][3][4]. In cancer models, elevated CDK11 expression has been reported in breast cancer, osteosarcoma, liposarcoma, and other malignancies, where CDK11 depletion suppresses proliferation, induces apoptosis, and disrupts cell-cycle progression[1][2][5]. Compared with related isoforms, CDK11^p110 is primarily associated with transcriptional and RNA-processing functions, whereas CDK11^p58 is linked to mitotic regulation, cytokinesis, cell-cycle arrest, and apoptosis-dependent processes[2][4]. This isoform distinction is particularly important in experimental cancer research because CDK11^p110 supports tumor-cell growth, while CDK11^p58 has been reported as a negative regulator in breast cancer models[2]. For research applications, RNA interference-mediated CDK11 silencing is widely used to evaluate tumor-cell dependency on CDK11 signaling, and emerging CDK11-targeted inhibitor studies further support its value as a therapeutic investigation platform[1][2][5].

CDK11 Related Products (7):

Cat. No. Product Name Effect Purity
  • HY-12467
    OTS964 hydrochloride
    		Inhibitor 99.74%
    OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC50 of 28 nM. OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM.
  • HY-X0009
    Tambiciclib
    		Inhibitor 99.21%
    Tambiciclib (GFH009, JSH-009) is an orally active, highly potent and selective CDK9 inhibitor (IC50 = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over DYRK1A/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC, and inducing apoptosis. Tambiciclib can be used for AML research.
  • HY-148061
    DB1113
    		99.86%
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity.
  • HY-150023
    BI-1622
    		Inhibitor 98.02%
    BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile.
  • HY-X0009A
    Tambiciclib dimaleate
    		Inhibitor 99.53%
    Tambiciclib (GFH009, JSH-009) dimaleate is an orally active, highly potent and selective CDK9 inhibitor (IC50 = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over DYRK1A/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib dimaleate demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC, and inducing apoptosis. Tambiciclib dimaleate can be used for AML research.
  • HY-182764A
    CDK11-IN-1 hydrochloride
    		Inhibitor
    CDK11-IN-1 hydrochloride is a potent, highly selective, and orally active CDK11 inhibitor with an IC50 of 4 nM, showing 32.5-fold and 2700-fold selectivity over CDK7 and CDK9, respectively. CDK11-IN-1 hydrochloride binds competitively to the ATP-binding pocket of CDK11 and forms a hydrogen bond with the hinge region residue Val163. It inhibits tumor cell proliferation and exhibits antitumor activity in lung cancer xenograft models. CDK11-IN-1 hydrochloride can be used for studies on the pathophysiology of CDK11-mediated tumors, as well as research on malignant tumors such as lung cancer.
  • HY-19718
    OTS964
    		Inhibitor
    OTS964 is an orally active, high affinity and selective TOPK inhibitor with an IC50 of 28 nM. OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM.